Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs

Prime Medicine, Inc.

2026-Q1 EPS reported -$0.28

Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.
Cash position $149.2M as of March 31, 2026, providing runway into 2027.
On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.
Appointed Svetlana Makhni as CFO in April 2026; regulatory dialogue ongoing for PM359 BLA.
Initial clinical data from PM577 and PM647 expected in 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Prime Medicine, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $49.1 million for the three months ended March 31, 2026.

Period: the quarter ended March 31, 2026
Net income: Net loss was $49.1 million for the three months ended March 31, 2026
Result: reported results

Exact text from the filing

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.

View on SEC.gov

Browse all earnings releases →

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.